Biology and pharmacology of the platelet P2Y12 receptor

Current Pharmaceutical Design

Volumn 12, Issue 10, 2006, Pages 1255-1259

  Storey, Robert F ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Antiplatelet effects; ATP; Clopidogrel; Platelet activation; Receptor operated cation channel

Indexed keywords

3 [7 [2 (3,4 DIFLUOROPHENYL)CYCLOPROPYLAMINO] 5 PROPYLTHIO 1,2,3 TRIAZOLO[4,5 D]PYRIMIDIN 3 YL] 5 HYDROXYMETHOXY 1,2 CYCLOPENTANEDIOL; ADENOSINE TRIPHOSPHATE; ADENOSINE TRIPHOSPHATE DERIVATIVE; ANTICOAGULANT AGENT; AR C 66096; AR C 66931 MX; ARL 66096; CALCIUM; CANGRELOR; CLOPIDOGREL; CYCLIC AMP; CYCLOPENTYLTRIAZOLOPYRIMIDINE; CYTOCHROME P450; DRUG METABOLITE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; FPL 66096; G PROTEIN COUPLED RECEPTOR; PADGEM PROTEIN; PRASUGREL; PROCOAGULANT; PURINE P2Y1 RECEPTOR; PURINE P2Y12 RECEPTOR; PURINE P2Y12 RECEPTOR ANTAGONIST; SEROTONIN; THIENOPYRIDINE DERIVATIVE; THROMBIN; THROMBOCYTE RECEPTOR; THROMBOXANE A2; TICLOPIDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANTITHROMBOCYTIC AGENT; MEMBRANE PROTEIN; P2RY12 PROTEIN, HUMAN; PURINE P2 RECEPTOR;

ACUTE CORONARY SYNDROME; ANTICOAGULATION; ARTERY THROMBOSIS; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG TARGETING; GENE AMPLIFICATION; GENETIC CODE; HEMOSTASIS; HUMAN; INFLAMMATORY DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RECEPTOR BLOCKING; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION; THROMBOCYTE LIFESPAN; THROMBOCYTE MEMBRANE; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; PHYSIOLOGY; THROMBOCYTE;

ANIMALS; BLOOD PLATELETS; HUMANS; MEMBRANE PROTEINS; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; RECEPTORS, PURINERGIC P2; TICLOPIDINE;

EID: 33744999455     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206776361318     Document Type: Review

References (69)

1. 12 Receptor A Novel Member of the P2Y Family of Receptors Activated by Extracellular Nucleotides. Mol Pharmacol 2001; 60: 416-420.
2. Daniel JL, Dangelmaier C, Jin J, Ashby B, Smith JB, Kunapuli SP. Molecular basis for ADP-indaced platelet activation: L Evidence for three distinct ADP receptors on human platelets. J Biol Chem 1998; 273: 2024-2029.
3. Kunapuli SP. Functional characterization of platelet ADP receptors. Platelets 1998; 9: 343-351.
4. Hollopeter G, Jantzen H-M, Vincent D, Li G, England L, Ramakrishnan V, et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001; 409: 202-207.
5. MacKenzie A, Mahaut-Smith MP, Sage SO. Activation of receptor-operated cation channels via P2X1 not P2T purinoceptors in human platelets. J Biol Chem 1996; 271: 2879-2881.
6. 1 receptors: evidence for separate receptors stimulated by ATP and ADP on human platelets. Br J Pharmacol 2000; 131: 108-114.
7. Vial C, Rolf MG, Mahaut-Smith MP, Evans RJ. A study of P2X1 receptor function in murine megakaryocytes and Human platelets reveals synergy with P2Y receptors. Br J Pharmacol 2002; 135: 363-372.
8. Oury C, Toth-Zsamboki E, Vermylen J, Hoylaerts MF. P2X1-mediated activation of extracelular signal-regulated kinase 2 contributes to platelet secretion and aggregation induced by collagen. Blood 2002; 100: 2499-2505.
9. Hechler B, Lenain N, Marchese P. Vial C, Heim V, Freund M, et al. A Role of the Fast ATP-gated P2X1 Cation Channel in Thrombosis of Small Arteries In vivo. J Exp Med 2003; 198: 661-667.
10. Jin J, Kunapuli SP. Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation. Proc Natl Acad Sci USA 1998; 95: 8070-8074.
11. Hechler B, Leon C, Vial C, Vigne P, Frelin C, Cazenave JP, et al. The P2Y1 receptor is necessary fbr adenosine-5′-diphosphate-induced platelet aggregation. Blood 1998; 92: 152-159.
12. 2T receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity. Br J Haematol 2000; 110: 925-934.
13. 1 receptor, necessary but not sufficient to support full ADP-induced platelet aggregation, is not the target of the drug clopidogrel. Br J Haematol 1998; 103: 858-866.
14. 1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets. J Biol Chem 1998; 273:2030-2034.
15. q-deficient mice. Nature 1997; 389: 183-186.
16. 13: Implications for collagen-induced platelet activation. J Biol Chem 2004; 279: 45354-9.
17. Savi P, Nurden P, Nurden A, Levy-Toledano S, Herbert JM. Clopidogrel: a review of its mechanism of action. Platelets 1998; 9: 251-255.
18. 2T receptor a novel approach to antithrombotic therapy. J Med Chem 1999; 42: 213-220.
19. 1-activated platelet adenylate cyclase in rats and rabbits. Thromb Haemost 1991; 65: 186-190.
20. 12 ADP-receptor. Journal of Thrombosis and Haemostasis 2004; 2: 135-146.
21. Trumel C, Payrastre B, Plantavid M, Hechler B, Vial C, Presek P, et al. A key role of adenosine diphosphate in the irreversible platelet aggregation induced by the PAR-1 activating peptide through the late activation of phosphoinositide 3-kinase. Blood 1999; 94: 4156-4165.
22. 3 integrin - a phosphoinositide 3-kinase-dependent mechanism. FEBS Lett 2001; 505: 281-290.
23. 2TAC receptors in ADP-evoked calcium signalling in human platelets. Cell Calcium 2000; 28: 119-126.
24. Paul BZS, Daniel JL, Kunapuli SP. Platelet shape change is mediated by both calcium-dependent and -independent signaling pathways. Role of p160 Rho-associated coiled-coil-containing protein kinase in platelet shape change. J Biol Chem 1999; 274: 28293-28300.
25. Furie B, Furie BC. The molecular basis of platelet and endothelial cell interaction with neutrophils and monocytes: role of P-selectin and the P-selectin ligand, PSGL-1. Thromb Haemost 1995; 74: 224-227.
26. Storey RF, Judge HM, Wilcox RG, Heptinstall S. Inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y12 receptor antagonist AR-C69931MX but not aspirin. Thromb Haemost 2002; 88: 488-494.
27. Klinkhardt U, Biuersachs R, Adams J, Graff J, Lindhoff-Last E, Harder S. Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with athrosclerotic; vascular disease. Clin Pharmacol Therapeut 2003; 73: 232-241.
28. Leon C, Ravanat C, Freund M, Cazenave JP, Gachet C. Differential involvement of the P2Y1 and P2Y12 receptors in platelet procoagulant activity. Arterioscler Thromb Vase Biol 2003; 23: 1941-1947.
29. Dangelmaier C, Jin J, Smith JB, Kunapuli SP. Potentiation of thromboxane A2-induced platelet secretion by Gi signaling through the phosphoinositide-3 kinase pathway. Thromb Haemost 2001; 85: 341-348.
30. Ramstrom S, Ranby M, Lindahl TL. Effects of inhibition of P2Y1 and P2Y12 an whole blood clotting, coagulum elasticity and fibrinolysis resistance studied with free oscillation rheometry. Thromb Res 2003; 109: 315-322.
31. Goto S, Tamura N, Eto K, Ikeda Y, Handa, S. Functional Significance of Adenosine 5′-Diphosphate Receptor (P2Y12) in Platelet Activation Initiated by Binding of von Willebrand Factor to Platelet GP Ib (alpha) Induced by Conditions of High Shear Rate. Circulation 2002; 105: 2531-2536.
32. Cattaneo M. Inherited platelet-based bleeding disorders. J Thromb Haemost 2003; 1: 1628-1636.
33. Cattaneo M, Akkawat B, Lecchi A, Cimminiello C, Capitanio AM, Mannucci PM. Ticlopidine selectively inhibits human platelet responses to adenosine diphosphate. Thromb Haemost 1991; 66: 694-699.
34. Boneu B, Destelle G, on behalf of the Study Group. Platelet antiaggregating activity and tolerance of clopidogrel in atherosclerotic patients. Thromb Haemost 1996: 76: 939-943.
35. Bertrand ME, Rupprecht H-J, Urban P, Gershlick AH, for the CLASSICS Investigators. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000; 102: 624-629.
36. Muller C, Buttner RJ, Petersten J, Roskamm H. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents. Circulation 2000; 101: 590-593.
37. Savi P, Beauverger P, Labouret C, Delfaud M, Salel V, Kaghad M, et al. Role of P2Y1 purinoceptor in ADP-induced platelet activation. FEBS Lett 1998; 422: 291-295.
38. Storey RF, Wilcox RG, Heptinstall S. Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease. Platelets 2002; 13: 407-413.
39. Proceedings of the International Society on Thrombosis and Haemostasis XXth Congress, Sydney 2005.
40. Bodor ET, Waldo GL, Hooks SB, Corbitt J, Boyer JL, Harden TK. Purification and Functional Reconstitution of die Human P2Y12 Receptor. Mol Pharmacol 2003; 64: 1210-1216.
41. 2T-purinoceptors. Br J Pharmacol 1994; 113: 1057-1063.
42. 2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. Thromb Haemost 2001; 85: 401-407.
43. Jacobsson F, Swahn E, Wallentin L, Dellborg M. Safety profile and tolerability of intravenous AR-C69931MX, a new antiplatelet drug, in unstable angina pectoris and non-Q-wave myocardial infraction. Clin Therapeut 2002; 24: 752-765.
44. Weaver WD, Harrington RA, Grines CL, Keeley EC, Kereiakes DJ, Bittl JA, et al. Intravenous AR-C69931MX, a novel P2T platelet receptor antagonist, in patients undergoing percutaneous coronary interventions - preliminary results from a placebo or active controlled trial. J Am Coll Cardiol 2000; 35 (Suppl A): 36.
45. 12 receptor antagonists. Haematologica 2004; 89 (Suppl 7): 13.
46. Guile SD. P2T receptor antagonists - towards novel orally active antithrombotics. Drug Dev Res 2000; 50 (Special Issue Purimes 2000): 14 (abstract).
47. Thebault JJ, Blatrix CE, Blanchard JF, Panak EA. Effects of ticlopidine, a new platelet aggregation inhibitor in man. Clin Pharmacol Ther 1975; 18: 485-490.
48. Schror K. The basic pharmacology of ticlopidine and clopidogrel Platelets 1993; 4: 252-261.
49. Thebault J-J, Kieffer G, Lowe GDO, Nimmo WS, Cariou. R. Repeated-dose pharmacodynamics of clopidogrel in healthy subjects. Sem Thromb Haemost 1999; 25 (Suppl 2): 9-14.
50. Thebault J-J, Kieffer G, Cariou R. Single-dose pharmacodynamics of clopidogrel. Sem Thromb Haemost 1999; 25 (Suppl 2): 3-8.
51. 2T antagonist AR-C69931MX. Haematologica 2000; 85 (Suppl): 92.
52. Muller L, Seyfarth M, Rudiger S, Wolf B, Pogatsa-Murray G, Schomig A, et al. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary gtent placement Heart 2001; 85: 92-93.
53. Savcic M, Hauert J, Bachmann F, Wyld PJ, Geudelin B, Cariou R. Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects. Sem, Thromb Haemost 1999; 25 (Suppl 2): 15-19.
54. Smith SMG, Judge HM, Peters G, Storey RF. Multiple antiplatelet effects of clopidogrel me not modulated by statin type in patients undergoing percutaneous coronary intervention. Platelets 2004; 15: 465-474.
55. Kastrati A, Mehilli J, Schuhlen H, Dirschinger J, Dotzer F, ten Berg JM, et al. A Clinical Trial of Abciximab in Elective Percutaneous Coronary Intervention after Pretreatment with Clopidogrel. N EngI J Mod 2004; 350: 232-238.
56. Caplain H, Donat F, Gaud C, Necciari J. Pharmacokinetics of clopidogrel. Sem Thromb Haemost 1999; 25 (Suppl 2): 25-28.
57. Savi P, Pereillo JM, Uzabiaga MF, Combalbert J, Picard C, Maffrand JP, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 2000; 84: 891-896.
58. Pereillo J-M, Maftouh M, Andrieu A, Uzabiaga M-F, Fedeli O, Savi P, et al. Structure and Stereochemistry of the Active Metabolite of Clopidogrel. Drug Metab Dispos 2002; 30: 1288-1295.
59. Lau WC, Gurbel PA, Watkins PB, Neer CJ, Hopp AS, Carville DGM, et al. Contribution of Hepatic Cytochrome P450 3A4 Metabolic Activity to the Phenomenon of Clopidogrel Resistance. Circulation 2004; 109: 166-171.
60. Taubert D, Kastrati A, Harlfinger S, Gorchakova O, Lazar A, von Beckerath N, et al. Pharmacokinetics of clopidogrel after administration of a high loading dose. Thromb Haemost 2004, 92: 311-316.
61. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for Coronary Stenting: Response Variability, Drug Resistance, and the Effect of Pretreatment Platelet Reactivity. Circulation 2003; 107: 2908-2913.
62. Fontana P, Dupont A, Gandrille S, Bachelot-Loza C, Reny J-L, Aiach M, et al. Adenosine Diphosphate-Induced Platelet Aggregation Is Associated With P2Y12 Gene Sequence Variations in Healthy Subjects. Circulation 2003; 108: 989-995.
63. Smith SMG, Judge HM, Peters G, Armstrong M, Fontana P, Gaussem P, et al. Clopidogrel therapy does not offset the platelet hypereactivity associated with common platelet receptor polymorphisms. Haematologica 2004; 89 (Suppl 7): 11.
64. Judge HM, Buckland RJ, Holgate CE, Storey RF. Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses. Platelets 2005, 16: 398-407.
65. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Cavallari U, Trabetti E, et al. Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease. Thromb Res 2005; 116: 491-497.
66. von Beckerath N, von Beckerath O, Koch W, Eichinger M, Schomig A, Kastrati A. P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose. Blood Coagal Fibrinol 2005; 16: 199-204.
67. Aga Y, Baba K, Tam S, Nakanishi T. Yoneda K, Kita J, Ueno H. UR-3216: a new generation oral platelet GPIIb/IIIa antagonist. Curr Pharm Des 2004; 10(14); 1597-601.
68. Turner CH, Robling AG. Exercise as an anabolic stimulus for bone. Curr Pharm Des 2004; 10(21): 2629-41.
69. Watala C. Blood platelet reactivity and its pharmacological modulation in (people with) diabetes mellitus. Curr Pharm Des 2005; 11(18): 2331-65.